Hemera receives Orphan Drug Designation for REMaST® therapy

Jun 8, 2023 | News

REMaST® recognized as an orphan drug for acute spinal injuries The advanced cell therapy REMaST® developed by Hemera has been granted orphan drug designation by the European Commission for the treatment of acute spinal cord injuries. This important recognition...

Changed the structure of the Board of Directors

May 8, 2023 | News

Hemera’s Board of Directors: Updates in its structure For personal reasons, Aldo Cocchiglia is leaving the Board of Directors, effective May 3, 2023. Two years after the birth of Hemera, the shareholders express their gratitude to Ing. Cocchiglia for his...

Hemera reaches an important milestone by obtaining the patent

Apr 21, 2023 | Uncategorized

The Italian Patent and Trademark Office has officially recognized the patent for the REMAST® therapy The positive evaluation of the Italian Patent and Trademark Office led to the expected recognition for the REMaST® therapy two years after the submission of the...